Comparison of the Improvement and Safety of the Ankle Brachial Arterial Pressure Index of Sarpogrelate and Clopidogrel in Stroke Patients With Decreased Ankle Brachial Arterial Pressure Index and Intermittent Claudication of Lower Limb Vascular Atherosclerosis.
Launched by EWHA WOMANS UNIVERSITY SEOUL HOSPITAL · May 16, 2024
Trial Information
Current as of February 18, 2025
Not yet recruiting
Keywords
ClinConnect Summary
A total of 100 subjects are recruited and divided into a intervention group and a control group through randomization.
In this clinical trial, the intervention group and the control group are assigned 1:1.
The researcher allocates 1:1 to the intervention group or control group through a two-way random number table on the assignment date in the order of the subjects who are satisfied with the Inclusion and exclusion criteria and agreed to the study.
This study is a prospective open randomized clinical trial that can confirm which group the subjects themselves were assigned to. After rando...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Aged 19 or over.
- • 2. Neurologically stable patients after 7 days and within 6 months of diagnosis of ischemic stroke.
- • 3. Patients with ankle-brachial index (ABI) \<0.9 performed within 6 months of screening, with lower limb vascular stenosis and intermittent claudication.
- • 4. A person who voluntarily agrees to participate in this clinical trial in writing.
- Exclusion Criteria:
- • 1. Patients who are unable or contraindicated to administer antithrombotic drugs.
- • 2. Patients with less than 80,000 platelets, less than 8.0 hemoglobin, liver levels and total bilirubin levels three times normal according to laboratory standards, according to blood tests conducted within one month.
- • 3. Patients identified as undergoing renal replacement therapy such as dialysis due to acute or terminal nephropathy during screening.
- • 4. Patients diagnosed with or treated for cancer within 6 months of screening, or identified as having recurrent or metastatic cancer.
- • 5. Patients confirmed to be on medication for liver diseases such as liver cirrhosis during screening.
- • 6. A pregnant and lactating women.
- • 7. Patients with a history of hemorrhagic tendency, conventional cerebral hemorrhage, and gastrointestinal hemorrhage.
- • 8. Patients who need oral anticoagulant therapy instead of antiplatelet drugs for screening.
- • 9. Patients who are at least 3 in the Rutherford category and need lower-limb vascular procedure/surgery within 6 months, as judged by the doctor.
- • 10. A patient with a loss of consciousness/cognition.
- • 11. Any person who determines that the tester is not suitable for participating in the clinical trial for other reasons.
About Ewha Womans University Seoul Hospital
Ewha Womans University Seoul Hospital is a leading academic medical institution in South Korea, dedicated to advancing healthcare through innovative research and clinical excellence. Affiliated with Ewha Womans University, the hospital combines cutting-edge medical practices with a strong emphasis on education and community service. The institution is committed to conducting rigorous clinical trials that enhance patient care and contribute to medical knowledge across various specialties. By fostering collaboration among healthcare professionals, researchers, and patients, Ewha Womans University Seoul Hospital aims to drive advancements in treatment and improve health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0